Danish pharmaceutical company H. Lundbeck’s (OTCPK:HLUYY)
(LUN.KO) first quarter is likely to be pretty much par for the course
for the near term – double-digit growth from its portfolio of newer
offsets that can’t offset the generic erosion of its old portfolio, with
investors hoping for updates on pipeline-building deals.
The
multiple misses in the growth portfolio were disappointing, but not
entirely surprising given the track record here. The deal for Abide
looks somewhat promising, but Lundbeck needs to do quite a bit more to
replenish its portfolio, and the clock is ticking with respect to patent
coverage on Northera (2021/22) and Trintellix (2026). Given where the
shares are, and the risks involved in recharging the portfolio, it’s
hard to make a compelling must-own case for these shares.
Click here for more:
Lundbeck, Like The Dude, Will Try To Abide
No comments:
Post a Comment